Speaker(s): 

Zackery P. Bulman, PharmD, Staff Member, University of Illinois Chicago - has disclosed Takeda Pharmaceuticals [Research Grant].

Moderator(s): 

Daniel Longyhore, PharmD, Ed.D., BCACP, Staff Member, Geisinger - has nothing to disclose.   

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• discuss the benefits of identifying bacterial resistance genes to provide patient-specific therapy through molecular rapid diagnostics.
• identify appropriate antibiotics for carbapenem-resistant Klebsiella pneumoniae with varying molecular resistance mechanisms.
• summarize the limitations of current treatment options for serious infections caused by carbapenem-resistant Klebsiella pneumoniae.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Daniel Longyhore, PharmD, Ed.D., BCACP; Eric Wright, PharmD, MPH; Melissa Kern, MPH; Lisabeth Karetsky, CPhT and Nichole Varela Gonzalez have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose.

Dean Parry, RPh and Kelly Shaw, PsyD; have nothing to disclose.

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant.